TY - JOUR
T1 - MRI free water as a biomarker for cognitive performance
T2 - Validation in the MarkVCID consortium
AU - Maillard, Pauline
AU - Hillmer, Laura J.
AU - Lu, Hanzhang
AU - Arfanakis, Konstantinos
AU - Gold, Brian T.
AU - Bauer, Christopher E.
AU - Kramer, Joel H.
AU - Staffaroni, Adam M.
AU - Stables, Lara
AU - Wang, Danny J.J.
AU - Seshadri, Sudha
AU - Satizabal, Claudia L.
AU - Beiser, Alexa
AU - Habes, Mohamad
AU - Fornage, Myriam
AU - Mosley, Thomas H.
AU - Rosenberg, Gary A.
AU - Singh, Baljeet
AU - Singh, Herpreet
AU - Schwab, Kristin
AU - Helmer, Karl G.
AU - Greenberg, Steven M.
AU - DeCarli, Charles
AU - Caprihan, Arvind
N1 - Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2022
Y1 - 2022
N2 - Introduction: To evaluate the clinical validity of free water (FW), a diffusion tensor imaging–based biomarker kit proposed by the MarkVCID consortium, by investigating the association between mean FW (mFW) and executive function. Methods: Baseline mFW was related to a baseline composite measure of executive function (EFC), adjusting for relevant covariates, in three MarkVCID sub-cohorts, and replicated in five, large, independent legacy cohorts. In addition, we tested whether baseline mFW predicted accelerated EFC score decline (mean follow-up time: 1.29 years). Results: Higher mFW was found to be associated with lower EFC scores in MarkVCID legacy and sub-cohorts (p-values < 0.05). In addition, higher baseline mFW was associated significantly with accelerated decline in EFC scores (p = 0.0026). Discussion: mFW is a sensitive biomarker of cognitive decline, providing a strong clinical rational for its use as a marker of white matter (WM) injury in multi-site observational studies and clinical trials of vascular cognitive impairment and dementia (VCID).
AB - Introduction: To evaluate the clinical validity of free water (FW), a diffusion tensor imaging–based biomarker kit proposed by the MarkVCID consortium, by investigating the association between mean FW (mFW) and executive function. Methods: Baseline mFW was related to a baseline composite measure of executive function (EFC), adjusting for relevant covariates, in three MarkVCID sub-cohorts, and replicated in five, large, independent legacy cohorts. In addition, we tested whether baseline mFW predicted accelerated EFC score decline (mean follow-up time: 1.29 years). Results: Higher mFW was found to be associated with lower EFC scores in MarkVCID legacy and sub-cohorts (p-values < 0.05). In addition, higher baseline mFW was associated significantly with accelerated decline in EFC scores (p = 0.0026). Discussion: mFW is a sensitive biomarker of cognitive decline, providing a strong clinical rational for its use as a marker of white matter (WM) injury in multi-site observational studies and clinical trials of vascular cognitive impairment and dementia (VCID).
KW - VCID
KW - biomarker
KW - diffusion tensor imaging
KW - free water
KW - small vessel disease
KW - vascular contributions to cognitive impairment and dementia
KW - white matter injury
UR - https://www.scopus.com/pages/publications/85145047473
UR - https://www.scopus.com/pages/publications/85145047473#tab=citedBy
U2 - 10.1002/dad2.12362
DO - 10.1002/dad2.12362
M3 - Article
C2 - 36523847
AN - SCOPUS:85145047473
SN - 2352-8729
VL - 14
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12362
ER -